UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

miR-221 promotes tumorigenesis in human triple negative breast cancer cells

PloS one, 2013-04, Vol.8 (4), p.e62170

2013

Link zum Volltext

Verfügbarkeit prüfen

A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications

Globalization and health, 2019-09, Vol.15 (1), p.57-57, Article 57

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of Project ECHO Models of Medical Tele-Education: a Systematic Review

Journal of general internal medicine : JGIM, 2019-12, Vol.34 (12), p.2842-2857

2019

Link zum Volltext

Verfügbarkeit prüfen

Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90

Clinical cancer research, 2011-08, Vol.17 (16), p.5432-5442

2011

Link zum Volltext

Verfügbarkeit prüfen

Targeting the mTOR pathway in tumor malignancy

Current cancer drug targets, 2013-03, Vol.13 (3), p.267

2013

Link zum Volltext

Verfügbarkeit prüfen

Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells

PloS one, 2012-10, Vol.7 (10), p.e48402

2012

Link zum Volltext

Verfügbarkeit prüfen

Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity

Cancer Immunology, Immunotherapy, 2012-10, Vol.61 (10), p.1721-1733

2012

Link zum Volltext

Verfügbarkeit prüfen

Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216

Clinical cancer research, 2014-02, Vol.20 (3), p.631-643

2014

Link zum Volltext

Verfügbarkeit prüfen

New York State 1115 Demonstration Independent Evaluation: Interim Report

Rand health quarterly, 2022-06, Vol.9 (3), p.5-5

2022

Link zum Volltext

Verfügbarkeit prüfen

Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design

ACS medicinal chemistry letters, 2013-01, Vol.4 (1), p.91-97

2013

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Novel, Potent, and Selective Inhibitors of 3-Phosphoinositide-Dependent Kinase (PDK1)

Journal of medicinal chemistry, 2011-12, Vol.54 (24), p.8490-8500

2011

Link zum Volltext

Verfügbarkeit prüfen

Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase

Bioorganic & medicinal chemistry letters, 2013-02, Vol.23 (4), p.1051-1055

2013

Link zum Volltext

Verfügbarkeit prüfen

Highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase

Bioorganic & medicinal chemistry letters, 2013-02, Vol.23 (4), p.1046-1050

2013

Link zum Volltext

Verfügbarkeit prüfen

Dual Functional Monoclonal Antibody PF-04605412 Targets Integrin α5β1 and Elicits Potent Antibody-Dependent Cellular Cytotoxicity

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24), p.10243-10254

2010

Link zum Volltext

Verfügbarkeit prüfen

Iliac venous stenting: antithrombotic efficacy of PD0348292, an oral direct Factor Xa inhibitor, compared with antiplatelet agents in pigs

Arteriosclerosis, thrombosis, and vascular biology, 2008-03, Vol.28 (3), p.413

2008

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4467: Targeting both PI3K/mTOR and EGFR pathways leads to synergistic anti-tumor activity in erlotinib resistant non-small-cell lung cancers

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4467-4467

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 126: miR-221 promotes tumorigenesis in human triple negative breast cancer cells

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.126-126

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3257: Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor, PF-4989216

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3257-3257

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3578: A novel and selective 3-phosphoinositide-dependent kinase-1 inhibitor, PF-5177624, blocks insulin-like growth factor-1 induced tumorigenesis in breast cancer cells

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3578-3578

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract A50: Targeting 3-phosphoinositide-dependent kinase-1 and mammalian target of rapamycin synergistically inhibits cell proliferation of breast cancer cells

Clinical cancer research, 2010-07, Vol.16 (14_Supplement), p.A50-A50

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4479: Targeting non-small cell lung cancer cells harboring a PIK3CA mutation by a novel and oral PI3K selective inhibitor, PF-4989216

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.4479-4479

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4473: PF-04691502, a potent and selective mTOR/PI3K dual inhibitor, demonstrates in vitro and in vivo antitumor activity in non-small cell lung carcinoma cells

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.4473-4473

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4482: Novel and selective small molecule inhibitors of 3-phosphoinositide-dependent kinase-1 inhibit the PDK-1/AKT signaling pathway and cell proliferation

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.4482-4482

2010

Link zum Volltext

Verfügbarkeit prüfen

Dual Inhibition of Blood Coagulation Factors Xa and Iia Synergize To Reduce Thrombus Weight and Thrombin Generation in a Rabbit Arteriovenous Shunt Model of Thrombosis

Blood, 2005-11, Vol.106 (11), p.1866-1866

2005

Link zum Volltext

Verfügbarkeit prüfen

Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24), p.10243-10254

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(14)
Humans
(13)
Animals
(9)
Mice
(7)
Oncology
(7)
Cell Line, Tumor
(6)
Protein Kinase Inhibitors - Pharmacology
(6)
Cancer
(5)
Chemistry, Medicinal
(5)
Female
(5)
Medicine
(5)
Pharmacology & Pharmacy
(5)
Antineoplastic Agents
(4)
Antineoplastic Agents - Pharmacology
(4)
Biological And Medical Sciences
(4)
Medical Sciences
(4)
Pharmacology. Drug Treatments
(4)
Proto-Oncogene Proteins C-Akt - Metabolism
(4)
Structure-Activity Relationship
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

miR-221 promotes tumorigenesis in human triple negative breast cancer cells

A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications

Impact of Project ECHO Models of Medical Tele-Education: a Systematic Review

Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90

Targeting the mTOR pathway in tumor malignancy

Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells

Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity

Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216

New York State 1115 Demonstration Independent Evaluation: Interim Report

Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design

Discovery of Novel, Potent, and Selective Inhibitors of 3-Phosphoinositide-Dependent Kinase (PDK1)

Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase

Highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase

Dual Functional Monoclonal Antibody PF-04605412 Targets Integrin α5β1 and Elicits Potent Antibody-Dependent Cellular Cytotoxicity

Iliac venous stenting: antithrombotic efficacy of PD0348292, an oral direct Factor Xa inhibitor, compared with antiplatelet agents in pigs

Abstract 4467: Targeting both PI3K/mTOR and EGFR pathways leads to synergistic anti-tumor activity in erlotinib resistant non-small-cell lung cancers

Abstract 126: miR-221 promotes tumorigenesis in human triple negative breast cancer cells

Abstract 3257: Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor, PF-4989216

Abstract 3578: A novel and selective 3-phosphoinositide-dependent kinase-1 inhibitor, PF-5177624, blocks insulin-like growth factor-1 induced tumorigenesis in breast cancer cells

Abstract A50: Targeting 3-phosphoinositide-dependent kinase-1 and mammalian target of rapamycin synergistically inhibits cell proliferation of breast cancer cells

Abstract 4479: Targeting non-small cell lung cancer cells harboring a PIK3CA mutation by a novel and oral PI3K selective inhibitor, PF-4989216

Abstract 4473: PF-04691502, a potent and selective mTOR/PI3K dual inhibitor, demonstrates in vitro and in vivo antitumor activity in non-small cell lung carcinoma cells

Abstract 4482: Novel and selective small molecule inhibitors of 3-phosphoinositide-dependent kinase-1 inhibit the PDK-1/AKT signaling pathway and cell proliferation

Dual Inhibition of Blood Coagulation Factors Xa and Iia Synergize To Reduce Thrombus Weight and Thrombin Generation in a Rabbit Arteriovenous Shunt Model of Thrombosis

Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity

Suchergebnisse filtern